Search

Search Constraints

You searched for: Author/Creator Pfisterer, Jacobus

Search Results

1. 2022-RA-285-ESGO Real world data of treatment and outcome of patients with early ovarian cancer (FIGO I) in Germany (QS Ovar of the AGO Study Group). (20th October 2022)

2. 2022-RA-420-ESGO Treatment and outcome of patients with high-grade advanced ovarian cancer (AOC) – real world data of the german quality assurance project (QS Ovar of the AGO Study Group). (20th October 2022)

4. Accelerating type‐specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high‐throughput tool for case review. Issue 5 (2nd September 2013)

5. Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: A metaanalysis of four prospective randomised phase III trials with 5114 patients. Issue 7 (May 2015)

6. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Issue 5 (May 2020)

7. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Issue 5 (May 2020)

8. Corrigendum to "Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group" [Eur J Cancer 49 (2013) 1905–1914]. (September 2016)

9. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). Issue 9 (12th April 2019)

10. EP222/#606 Acid ceramidase (ASAH1) expression is associated with improved overall survival in patients with high-grade serous ovarian cancer from the ICON-7 trial. (4th December 2022)